What regulatory milestone did Cynata Therapeutics (ASX:CYP) just achieve?

Cynata Therapeutics received a Positive Opinion from the European Medicines Agency’s Paediatric Committee (PDCO). This decision formally approves the Paediatric Investigation Plan (PIP) for its flagship cell therapeutic product, CYP-001.

Why is this European Medicines Agency decision critical for Cynata Therapeutics (ASX:CYP)?

Securing an agreed PIP is a mandatory regulatory prerequisite before any company can commence Phase 3 clinical trials in the European Union. Without this approval, Cynata could not advance its flagship candidate into late-stage European trials for either adults or children.

What is CYP-001 and what medical condition does it treat?

CYP-001 is Cynata’s proprietary stem cell product designed to modulate the immune system to treat acute graft-versus-host disease (aGvHD). This condition is a life-threatening bone marrow transplant complication where donor immune cells attack the recipient's tissues.

How large is the market opportunity and clinical need for Cynata's CYP-001?

The clinical need is high, as standard steroid treatments fail in about 50% of aGvHD cases, leading to steroid-resistant aGvHD. This resistant form is historically devastating, carrying a dismal two-year survival rate of under 20%.

What are the key details of Cynata’s approved paediatric clinical trial?

The agreed PIP outlines a single randomised controlled Phase 2/3 clinical trial. It will enroll approximately 72 paediatric patients ranging in age from 28 days to 18 years old.

What is Cynata’s clinical rollout strategy for adults versus children?

Cynata plans to launch a Phase 3 trial in adults initially. The paediatric trial will commence immediately following the completion of the primary analysis from that adult Phase 3 trial.

Image for illustrative purposes only. Not a real photo.

Cynata secures European paediatric regulatory approval

Written by Liezl GambePublished Jun. 3 2026Last Updated Jun. 3 2026

Cynata Therapeutics (ASX:CYP) has received a positive opinion from the European Medicines Agency’s paediatric committee.

The decision approves the Paediatric Investigation Plan for its flagship cell therapeutic, CYP-001, targeting acute graft-versus-host disease.

The regulatory endorsement is a mandatory prerequisite before commencing Phase 3 clinical trials within the European Union.

The agreed PIP outlines a single randomised controlled Phase 2/3 trial involving approximately 72 paediatric patients aged 28 days to 18 years.

Cynata’s development strategy involves initiating a Phase 3 trial in adults first, with the paediatric trials commencing immediately after the primary analysis of the adult cohort.

The agreed timeline permits Cynata to submit its marketing authorisation application for adults while the paediatric study remains ongoing.

CYP-001 utilises Cynata’s proprietary Cymerus iPSC-derived mesenchymal stem cell technology to modulate the immune system.

It addresses aGvHD, a life-threatening bone marrow transplant complication where donor cells attack recipient tissues.

Standard steroid treatments fail in half of all cases, resulting in steroid-resistant aGvHD, which carries a dismal historical two-year survival rate of under 20%.

Cynata’s Phase 1 adult trial demonstrated an impressive 87% overall response rate and a 60% two-year survival rate with no serious adverse safety concerns.

Results from a 65-patient Phase 2 adult trial are eagerly anticipated in late June or early July 2026.

At the time of reporting, Cynata Therapeutics’ share price was $0.28.